2% from the prior year quarter due to. diagnostic radiopharmaceutical. Lantheus Holdings, Inc. 6 million to the ante. The company is well-positioned to generate substantial free cash flow The cash flow statement provides a detailed overview of the cash inflows and outflows of a company over a specified period. It is the #1 PSMA PET Imaging. “2022 was an outstanding year for Lantheus, led by the success of PYLARIFY and expansion of our Radiopharmaceutical Oncology pipeline. The recommended PYLARIFY dose is 333 MBq (9 mCi) with an acceptable range of 296 MBq to 370 MBq (8 mCi to 10 mCi), administered as a bolus intravenous injection. (the “Company”) (NASDAQ: LNTH), an established leader and fully. As a leader in the development, manufacture and commercialization of pioneering diagnostic and therapeutic products, we’re determined to Find, Fight and Follow ® a broad range of diseases. Third quarter operating cash. , Nov. PYLARIFY AI deployment can be facilitated both as a secure web cloud application and as a local. (NASDAQ:NASDAQ:LNTH) Q4 2021 Earnings Conference Call February 24, 2022 8:00 AM ETCompany ParticipantsMary Anne Heino – President and Chief Executive Officer Mark. , Progenics Pharmaceuticals, Inc. 4% from the prior year period ; GAAP net income of $61. PYLARIFY PSMA - Where and when. Worldwide revenue of $102. Hours: 8:30 am to 8:00 pm ET, Monday to Friday. S. COMPANY IDENTIFICATION: Progenics Pharmaceuticals, Inc. Based in North Billerica, Mass. FDA Approval of PYLARIFY® (piflufolastat F 18) Injection, the First and Only Commercially Available PSMA PET. “The data we presented at ASCO GU emphasize the clinical utility of piflufolastat F 18 to. PYLARIFY AI is an FDA-cleared artificial intelligence platform developed to assist in standardized quantification of PSMA PET/CT scans. PYLARIFY AI™ (aPROMISE) is the only deep learning enabled FDA-cleared medical device software to offer standardized PSMA PET reporting with PYLARIFY AI on PSMA PET/CT images, including those. Lantheus Holdings, Inc. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY ® Vial for (Perflutren Lipid Microsphere) Injectable. For more information, visit Contacts: Mark Kinarney Vice President, Investor Relations 978-671-8842 [email protected] has multiple products on the market with two standouts driving the most growth with Pylarify and Definity. Eastern Time. Image source: The Motley Fool. “Lantheus delivered another strong quarter and full year, highlighted by revenue performance which increased 38% and 25%, respectively,” said Mary Anne Heino, President and CEO. An FDA-cleared medical device software, PYLARIFY AI V1. 4. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY ® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; PYLARIFY ®, a PSMA PET imaging. 01. S. ” Prostate cancer is a common and usually slow-growing cancer. The program is available to HCPs who have completed the PYLARIFY® Reader Training. Before that Lantheus, which has operated since the 1950s, relied on established businesses in microbubbles and spect imaging. “We successfully launched PYLARIFY, which we believe is the best-in-class PSMA PET imaging agent for prostate cancer, maintained our revenue growth and. Lantheus (LNTH) stock rose ~17% on Thursday after Q4 results beat estimates and the FY23 outlook was placed above expectations. PYLARIFY® (piflufolastat F 18) Injection is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer: with suspected metastasis who are candidates for initial definitive therapy. 9% sodium chloride injection USP. 1-800-299-3431. LNTH-1095 (also known as MIP-1095) is a small molecule PSMA-targeted 131 I-based radioligand therapy for the treatment of metastatic castration-resistant prostate cancer (mCRPC) which combines a PSMA-targeted ligand, LNTH-1095, with the beta-emitting radioisotope 131 I. Quote. Lantheus Receives U. DEFINITY closed out 2022 with $245 million of net sales, an increase of 5. As a result of the net sales generated by PYLARIFY in 2022, the maximum aggregate cash payment of $99. The company's. 48 from the prior year period. 2 million for the third quarter 2022, compared to GAAP net loss of $13. Product Uses: diagnostic radiopharmaceutical . 89 for the second quarter of 2022, representing an increase of approximately $0. PYLARIFY injection is a fluorinated small molecule PSMA-targeted PET imaging agent that enables visualization of lymph nodes, bone and soft tissue metastases to determine the presence of recurrent and/or metastatic prostate cancer. , Professor of Urology, University of California San DiegoLantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY ® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; PYLARIFY ®, a PSMA PET imaging. 29, 2021 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. 8 million for the first quarter 2023, representing an increase of 44. The approval covers the use of Lu177-PSMA-617 in patients who have metastatic prostate cancer that is hormone-resistant (also known as castrate-resistant) and whose tumors. “PYLARIFY AI is the first and only FDA-cleared medical device software that offers a standardized platform for quantifying PSMA PET/CT images,” said Mary Anne Heino, President and Chief Executive Officer of Lantheus. com. S. Lantheus Holdings, Inc. LNTH is scheduled to release third-quarter 2023 results on Nov 2, before the opening bell. 86 for the third quarter 2022, compared to. Lantheus Receives U. 0. The. Worldwide revenue of $263. com. 3% over the prior year. 7 million for the second quarter 2023, representing an increase of 43. Lantheus experienced tremendous growth in last 2 years thanks to the approval of a new imaging agent called PYLARIFY. EMERGENCY PHONE: CHEMTREC 1-800-424-9300. Piflufolastat F 18 (PYLARIFY®) is an 18F-labelled diagnostic imaging agent that has been developed by Progenics Pharmaceuticals Inc. Frederic Pouliot, Hospitalier Universitaire (CHU) de Québec-Université Laval. Progenics Pharmaceuticals, Inc. The Lantheus Protocol: Pylarify Growth May Slow. Even if Bracco were to secure 40%+ share in an expanding F-18 PSMA PET imaging market over the next 3 years, the Truist team still thinks Pylarify and Lantheus are undervalued, especially with the. , Nov. Lastly, net cash provided by operating activities was $108. News release. The Company updates its guidance for the first quarter and full year 2023 is as follows: PYLARIFY revenues in 1H23 were $405m - up 82% year-on-year - so it seems clear that PYLARIFY revenues have substantially more growth potential - Lantheus' guidance for total revenues in 2023. to 6:00 p. NORTH BILLERICA,. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY ® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; PYLARIFY ®, a PSMA PET imaging agent for the detection of suspected recurrent or metastatic prostate cancer; TechneLite ® (Technetium Tc99m Generator), a technetium-based generator. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY ® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; PYLARIFY ®, a PSMA PET imaging. FDA Approval of PYLARIFY® (piflufolastat F 18) Injection, the First and Only Commercially Available PSMA PET Imaging Agent for Prostate Cancer May 27, 2021 PYLARIFY will be available immediately to imaging centers in parts of the mid- Atlantic and southern regions and is expected to be broadly availableLantheus delivered a BIG and welcome beat-and-raise quarter and shares were up as much as +20%, poking their nose over $71. 3% from the prior year period. 00. U. PYLARIFY® (piflufolastat F 18) Injection is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer: with suspected metastasis who are candidates for initial definitive therapy. PDF Version. OSPREY was a robust, prospective, multicenter, phase 2/3 clinical trial of 385 men with either high-risk prostate cancer (Cohort A; n=268) or radiologic evidence of recurrence (Cohort B; n=117) OSPREY assessed the sensitivity, specificity, PPV, and NPV in pelvic lymph nodes for PYLARIFY® PET/CT. PYLARIFY is the first and only commercially available, FDA-approved PSMA-targeted PET imaging agent for prostate cancer. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY ® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; PYLARIFY ®, a PSMA PET imaging agent for the detection of suspected recurrent or metastatic prostate cancer; TechneLite ® (Technetium Tc99m Generator), a. m. Lantheus Holdings, Inc. [Image courtesy of Lantheus] Lantheus is a developer of AI-powered diagnostic and therapeutic products. NORTH BILLERICA, Mass. Please enter your ZIP code to locate the nearest imaging site that offers PYLARIFY®. This is the first and final payment related to the CVRs and is in full satisfaction of Lantheus’ payment obligations related to the CVRs. 28 May, 2021, 07:00 ET. Leading the way for Lantheus is PYLARIFY, which delivered sales of $210. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY ® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; PYLARIFY ®, a PSMA PET imaging. • Dispose of any unused PYLARIFY in compliance with applicable regulations. com. . In 2023, PYLARIFY, the #1 PSMA PET imaging agent and DEFINITY, the #1 ultrasound enhancing agent, will continue to deliver value for our patients, healthcare professionals, employees, and shareholders. Comparison of Gallium-68 and Fluorine-18 imaging characteristics in positron emission. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY ® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; PYLARIFY ®, a PSMA PET imaging. Lantheus says its technology can help improve the management of prostate cancer patients. PYLARIFY works by binding to PSMA, a protein that is overexpressed on the surface of more than 90% of primary and metastatic prostate cancer cells. “Lantheus is leading the way in harnessing the power of AI and machine learning technologies, together with our game-changing PSMA-targeted PET imaging agent PYLARIFY, to potentially transform the way that clinicians manage and treat prostate cancer,” said Jean-Claude Provost, MD, Interim Chief Medical Officer, Lantheus. --(BUSINESS WIRE)--Dec. 1 million, or $0. Lantheus Receives U. Lantheus presented study results providing independent validation of PYLARIFY AI™, the Company’s artificial intelligence (AI) platform developed to assist in standardized quantification of PSMA PET/CT scans. 22, 2021 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ET. We reported revenue of $319. PYLARIFY AI is an FDA-cleared medical device software and is commercially available in the United States. Lantheus Announces Presentations Featuring PYLARIFY® (Piflufolastat F18), PYLARIFY AI™ and NM-01 (PD-L1 Imaging) at the 2022 Society for Nuclear. In the U. February 10, 2022 17:33 ET | Source: Lantheus Holdings, Inc. Diagnostic performance of 18 F-DCFPyL-PET/CT in men with biochemically recurrent prostate cancer: results from the CONDOR phase III, multicenter study. United States of America . 01, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. EMERGENCY PHONE: CHEMTREC 1-800-424-9300. 9% Sodium Chloride Injection, USP. 7 million in the prior year period ; GAAP fully diluted net income per share of $0. FDA Approval of PYLARIFY® (piflufolastat F 18) Injection, the First and Only Commercially Available PSMA PET Imaging Agent for Prostate Cancer May 27, 2021 PYLARIFY will be available immediately to imaging centers in parts of the mid- Atlantic and southern regions and is expected to be broadly available68. Assay the dose in a suitable dose calibrator prior to administration. The Company’s worldwide revenue for the fourth quarter of 2022 totaled $263. Piflufolastat F 18 (PYLARIFY®) is an 18F-labelled diagnostic imaging agent that has been developed by Progenics Pharmaceuticals Inc. Lantheus presented study results providing independent validation of PYLARIFY AI™, the Company’s artificial intelligence (AI) platform developed to assist in standardized quantification of. Lantheus Holdings, inc ( LNTH 2. 3 million for the third quarter 2022, representing an increase of 134. By Kate Stalter • Oct 28, 2022LNTH earnings call for the period ending September 30, 2021. 0% from the prior year period. February 16, 2023 at 8:30 AM EST. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY ® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; PYLARIFY ®, a PSMA PET imaging agent for the detection of suspected recurrent or metastatic prostate cancer; PYLARIFY AI™, an artificial intelligence platform. COMPANY IDENTIFICATION: Progenics Pharmaceuticals, Inc. 7 million for the second quarter 2022, representing an increase of 121. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY ® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; PYLARIFY ®, a PSMA PET imaging agent for the detection of suspected recurrent or metastatic prostate cancer; TechneLite ® (Technetium Tc99m Generator), a. PYLARIFY is used along with positron emission tomography (PET) imaging for men with prostate cancer: with suspected metastasis who are candidates for initial definitive therapy. S. It describes its PYLARIFY injection as “a radioactive diagnostic agent indicated. PYLARIFY® CODING AND BILLING GUIDE | PYLARIFY® Reimbursement Hotline: 844-339-8514 PYLARIFY® and the associated services provided in a physician office are billed on the CMS-1500 claim form or its electronic equivalent. , May 11, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. BEDFORD, Mass. In May 2021, the FDA approved the PSMA PET imaging agent piflufolastat F 18 (Pylarify) for identifying suspected metastasis or recurrence of prostate cancer. Visit Investor Site. PYLARIFY AI is an FDA-cleared artificial intelligence platform developed to assist in standardized quantification of PSMA PET/CT scans. The Company’s first quarter 2023 adjusted fully diluted net income per share, or earnings per share (“EPS”), was $1. D. INDICATION. PYLARIFY may be diluted with 0. , [18 F]-DCFPyL was approved by the FDA in May of 2021 and is commercially available as PYLARIFY ® (Piflufolastat F 18 Injection) and sold by Lantheus. About Lantheus With more than 65 years of experience in delivering life. , Nov. GAAP. Lantheus Holdings, Inc. "It's not like there is only one PSMA molecule that we can radiolabel," said Cameron Foster, director of theranostics at the University of California, Davis. 1-800-299-3431. 3% over the prior year. The program is available to HCPs who have completed the PYLARIFY® Reader Training. Customer Support at 1-800-964-0446 M-F 8:30 am-8:00 pm EST, or email cspyl@lantheus. 1 million for the second quarter 2022, compared to GAAP net loss of $26. Lantheus Holdings, Inc. Worldwide revenue of $239. PYLARIFY AI™ (aPROMISE) is the only deep learning enabled FDA-cleared medical device software to offer standardized PSMA PET reporting on PSMA PET/CT images, including those achieved using. 12. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY ® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; PYLARIFY ®, a PSMA PET imaging. Worldwide revenue of $208. , Sept. Purpose of this notice. m. ir@lantheus. Lantheus Holdings Inc (NASDAQ:LNTH) made significant progress during the quarter with PYLARIFY and DEFINITY in its commercial portfolio, and with PNT2002 and MK-6240 in its pipeline. 4% from the prior year period. 45 and $0. PYLARIFY® (piflufolastat F 18) Injection is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men. It is worth mentioning that PYLARIFY is an F 18-labelled PSMA-targeted. May 27, 2021 — Today, the FDA approved the 18F-DCFPyL PSMA PET imaging agent (also known as “PyL” for short or by its trade name “PYLARIFY”). with suspected recurrence based on. The PyLAM is the primary customer facing Lantheus Holdings professional tasked with education of the Prostate Cancer medical referral community on PyLARIFY and the cultivation of productive customer relationships to include HCPs, Advanced Practice Providers, Nurses, Pharmacists, Department Administrators and other key medical and. It is used to determine the presence or absence of recurrent or metastatic prostate cancer. Lantheus Holdings, Inc. Their experience with these complex products and established footprint in commercializing PYLARIFY and AZEDRA makes them an ideal collaborator for these programs,” said Joe McCann, Ph. For International Transportation Emergencies Call CC-BY-4. PYLARIFY, AZEDRA, DEFINITY/LUMINITY, Xenon-133, NEUROLITE, TechneLite, Cardiolite, developmental products: United States. PYLARIFY AI is an FDA-cleared medical device software and is commercially available in the United States. 1. Even if Bracco were to secure 40%+ share in an expanding F-18 PSMA PET imaging market over the next 3 years, the Truist team still thinks Pylarify and Lantheus are undervalued, especially with the. PYLARIFY AI™ (aPROMISE) is the only deep learning enabled FDA-cleared medical device software to offer standardized PSMA PET reporting with PYLARIFY AI on PSMA PET/CT images, including those. Billerica, MA 01862 . 50 from the prior year period. Jul. “This. While the company generated $527M in revenue from Pylarify, revenue from its other radiopharmaceutical oncology products reached $4. A sample CMS-1500 claim form for billing PYLARIFY® is provided below. 4% from the prior year period; GAAP net income of $43. 4 million in the prior year period ; GAAP fully diluted net income per share of $0. Risks and uncertainties that could cause our actual results to materially differ from those described in the forward-looking statements include: (i) continued market expansion and penetration for our established commercial products, particularly PYLARIFY and DEFINITY, in a competitive environment in which other imaging agents have been approved. Lantheus Receives U. 23, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ENVX, GSM, AMC, LAZR, and LNTH. NORTH BILLERICA, Mass. PYLARIFY® (piflufolastat F 18) Injection Indication PYLARIFY® (piflufolastat F 18) Injection is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer:. Before that Lantheus, which has operated since the 1950s, relied on established businesses in microbubbles and spect imaging. This is an increase of 200% compared to the previous 30 days. • Assay the dose in a suitable dose calibrator prior to administration. Worldwide revenue of $300. In. Lantheus has offices in Massachusetts, New Jersey, Canada and Sweden. Lantheus’ product, PYLARIFY ® (piflufolastat F 18) injection, is a radioactive diagnostic agent indicated for PET imaging of PSMA positive lesions in men with prostate cancer: with suspected metastasis who are candidates for initial definitive therapy and/or with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level. S. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY ® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; PYLARIFY ®, a PSMA PET imaging agent for the detection of suspected recurrent or metastatic prostate cancer; TechneLite ® (Technetium Tc99m Generator), a. Paul joined Lantheus in 2020 and has been an exemplary leader throughout his tenure, demonstrating strong strategic and leadership skills, most notably with the very successful launch of PYLARIFY. In the U. “The transaction leverages Lantheus’. For the full year 2022, Lantheus forecasts PYLARIFY to be in a range of $300M to $325M and their. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; PYLARIFY®, a PSMA PET imaging agent. PYLARIFY is a sterile, non-pyrogenic, clear, colorless solution for intravenous injection. with suspected recurrence based on elevated serum levels of prostate-specific antigen (PSA) level. 2 million for the fourth quarter and full year 2021, representing an increase of 37. Pylarify (piflufolastat), which was approved in 2021 by the Food and Drug Administration, is a. Customer Support at 1-800-964-0446 M-F 8:30 am-8:00 pm EST, or email cspyl@lantheus. GAAP net loss. S. This sample claim form is only an example. 66 from the prior year period. MarketBeat Follows Only 4 people have added Lantheus to their MarketBeat. Lantheus Reports First Quarter 2023 Financial Results. 3M as the prostate cancer diagnostic agent Pylarify added $143. 9, 2020-- Lantheus Holdings, Inc. 2% from the prior year quarter due to. Morris MJ, Rowe SP, Gorin MA, et al. S. PDF Version. com. (the Company) (NASDAQ: LNTH), a company committed to improving patient outcomes. , Nov. “Lantheus is leading the way in harnessing the power of AI and machine learning technologies, together with our game-changing PSMA-targeted PET imaging agent PYLARIFY, to potentially transform. 29. The company believes the approval of a PSMA-targeted therapeutic for the treatment of adult patients with PSMA-positive metastatic castration. 01. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; PYLARIFY®, a PSMA PET imaging agent. Leadership provided initial guidance for FY2023 as well. But. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY ® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; PYLARIFY ®, a PSMA PET imaging agent for the detection of suspected recurrent or metastatic prostate cancer; TechneLite ® (Technetium Tc99m Generator), a. S. 2 million, or $0. 8% from the prior year period; GAAP net income of $94. 4% from the prior year period ; GAAP net income of $61. In the U. Read more about Lantheus Announces Top Rated Oral Presentation. Deploy. With 3 million men living with prostate cancer and more than 18 million adults. S. The PyLAM is the primary customer facing Lantheus Holdings professional tasked with education of the Prostate Cancer medical referral community on PyLARIFY and the cultivation of productive customer relationships to include HCPs, Advanced Practice Providers, Nurses, Pharmacists, Department Administrators and other key medical and. S. Contact information For media. 47, as compared to $0. It will need to spend additional. Lantheus presented study results providing independent validation of PYLARIFY AI™, the Company’s artificial intelligence (AI) platform developed to assist in standardized quantification of PSMA PET/CT scans. 1% over the. 4. PYLARIFY AI™ is intended to be used by healthcare professionals and researchers for acceptance, transfer, storage, image display, manipulation, quantification and reporting of digital medical images. 86 for the third quarter 2022, compared to. com. 4 million in the prior year period ; GAAP fully diluted net income per share of $0. (NASDAQ: LNTH) (Lantheus), the parent company of Lantheus Medical Imaging, Inc. , Sept. COMPANY IDENTIFICATION: Progenics Pharmaceuticals, Inc. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY ® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; PYLARIFY ®, a PSMA PET imaging. Lantheus said its worldwide revenue for the period rose ~134% YoY to $239. ATLANTA, March 31, 2022 /PRNewswire-PRWeb/ -- Syntermed is proud to. . S. [email protected] provides a broad portfolio of products, including the echocardiography agent DEFINITY ® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; PYLARIFY ®, a PSMA PET imaging agent for the detection of suspected recurrent or metastatic prostate cancer; TechneLite ® (Technetium Tc99m Generator), a. 2% for the week as of Friday afternoon,. Phone: 1-800-964-0446. Customer Service: 1-800-299-3431: Hours: 7:30 a. We are conducting a phase 2 trial of LNTH-1095 in mCRPC pre. Coordination of care. (“Lantheus”) (NASDAQ: LNTH), a company committed to improving. 86 per fully diluted share, as compared to GAAP net loss of. 3 million for the second quarter 2023. A sample CMS-1500 claim form for billing PYLARIFY® is provided below. PYLARIFY is used along with positron emission tomography (PET) imaging for men with prostate cancer: with suspected metastasis who are candidates for initial definitive therapy. While the company generated $527M in. , June 12, 2023 (GLOBE NEWSWIRE) — Lantheus Holdings, Inc. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY ® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; PYLARIFY ®, a PSMA PET imaging agent for the detection of suspected recurrent or metastatic prostate cancer; TechneLite ® (Technetium Tc99m Generator), a technetium-based generator. Lantheus presented study results providing independent validation of PYLARIFY AI , the Company s artificial intelligence (AI) platform developed to assist in standardized quantification of PSMA PET/CT scans. 9% Sodium Chloride Injection USP. Lantheus Announces Presentations Featuring PYLARIFY AI™ at the 2023 Society for Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting June 12,. Frederic Pouliot, Hospitalier Universitaire (CHU) de Québec-Université Laval. Lantheus to Host Third Quarter 2023 Earnings Conference Call and Webcast on November 2, 2023, at 8:00 a. 1 million for the fourth quarter and full year 2022, representing increases of 103. Indication PYLARIFY ® (piflufolastat F 18) Injection is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY ® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; PYLARIFY ®, a PSMA PET imaging. price-eps-surprise | Lantheus Holdings, Inc. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY ® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; PYLARIFY ®, a PSMA PET imaging. 1 million in the prior year period; GAAP fully diluted net income per share of $1. The Pylarify AI system is a deep learning algorithm that allows physicians to. Do not use if it contains particulate matter or if it is discolored (PYLARIFY is a clear, colorless solution). This agent is similar to the Gallium-68 PSMA-11 agent which was approved in December 2020, except that it can be produced in much greater quantities and distrMarketBeat has tracked 5 news articles for Lantheus this week, compared to 5 articles on an average week. 52%) were up 21. Each milliliter contains 37 to 2,960 MBq (1 to 80 mCi) piflufolastat F 18 with ≤0. B Riley has resumed coverage of Lantheus Holdings (NASDAQ:LNTH) with a buy citing the company's growth trajectory due to the the launch of Pylarify, a prostate-specific membrane antigen (PSMA. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY ® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; PYLARIFY ®, a PSMA PET imaging agent for the detection of suspected recurrent or metastatic prostate cancer; PYLARIFY AI™, an artificial intelligence platform that assists in the. Lantheus has offices in Massachusetts, New Jersey, Canada and Sweden. 1M in 2022, following a 25% YoY decline, according to the. U. Lantheus market research and analysis with ordering physicians, NCCN, ACS, UpToDate, SEER. 9% Sodium Chloride Injection, USP. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY ® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; PYLARIFY ®, a PSMA PET imaging. We have been thrilled with the response to PYLARIFY in the prostate cancer community, said Mary Anne Heino, President and Chief Executive Officer of Lantheus. 22, 2021 (GLOBE NEWSWIRE) -- Lantheus Holdings. Eastern Time. Leading the way for Lantheus is PYLARIFY, which delivered sales of $210. Lantheus Holdings, which belongs to the Zacks Medical - Products industry, posted revenues of $300. Search Interest 21 people have searched for LNTH on MarketBeat in the last 30 days. 7 million in the same period last year. 15. 9% Sodium Chloride Injection USP. istering PYLARIFY. TechneLite net revenue was $24. In hindsight it appears that the sellside failed to appreciate Pylarify's potential. BEDFORD, Mass. The Company’s first quarter 2023 adjusted fully diluted net income per share, or earnings per share (“EPS”), was $1. The Company’s third quarter 2023 adjusted fully diluted net income per share, or earnings per share (“EPS”), was $1. Lantheus Holdings, Inc. We accelerated our growth, diversified our portfolio, and delivered record revenues and profits which created additional free cash flows,” said Mary Anne Heino, President and Chief Executive Officer. The company expects to. 01, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. The device provides general. The FDA approved the F 18-labeled prostate-specific membrane antigen (PSMA)–targeted positron emission tomography (PET) imaging agent 18F-DCFPyL (Pylarify) for use in prostate cancer, according to an announcement from the company responsible for the agent, Lantheus Holdings, Inc. Lantheus Receives U. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; PYLARIFY®, a PSMA PET imaging agent for the detection of suspected recurrent or metastatic prostate cancer; PYLARIFY AI™, an artificial intelligence platform. , June 12, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. PYLARIFY AI is an FDA-cleared artificial intelligence platform developed to assist in standardized quantification of PSMA PET/CT scans. PDF. Lantheus Holdings on Thursday reported Q4 adjusted net income of $1. 0 million and $150. , a Lantheus company. (the Company) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, announced PYLARIFY AI data will be presented at the. by year. NORTH BILLERICA, Mass. (the Company) (NASDAQ: LNTH), a company committed to“PYLARIFY AI has the potential to contribute meaningful insights to inform treatment selection and monitoring in prostate cancer. Lantheus has offices in Massachusetts, New Jersey, Canada and Sweden. GAAP net. Shares of Lantheus Holdings (LNTH-0. 3% over the prior. Lantheus Holdings. Intended for U. 's (LNTH) PYLARIFY injection, a prostate specific membrane antigen-targeted positron emission tomography imaging agent, has been approved by the FDA. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY ® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; PYLARIFY ®, a PSMA PET imaging agent for the detection of suspected recurrent or metastatic prostate cancer; TechneLite ® (Technetium Tc99m Generator), a. PYLARIFY AI is an FDA-cleared artificial intelligence platform developed to assist in standardized quantification of PSMA PET/CT scans. 0 is commercially available in the United States . 0 million and $150. Lantheus receives US FDA approval of PYLARIFY (piflufolistat F 18) injection, the first and only commercially available PSMA PET imaging agent for prostate cancer. LinkedIn. S. The PyLAM is the primary customer facing Lantheus Holdings professional tasked with education of the Prostate Cancer medical referral community on PyLARIFY and the cultivation of productive customer relationships to include HCPs, Advanced Practice Providers, Nurses, Pharmacists, Department Administrators and other key medical and. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY ® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; PYLARIFY ®, a PSMA PET imaging. PYLARIFY (piflufolastat F18) injection. 0. PYLARIFY (piflufolastat F 18) injection (also known as 18 F-DCFPyL or PyL) is a fluorinated small molecule PSMA-targeted PET imaging agent that enables visualization of lymph nodes, bone and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. S. , May 28, 2021 /PRNewswire/ -- SOFIE, an established Radiopharmaceutical Contract Manufacturing Organization and GMP radiopharmacy network, will be commercially. Lantheus provides a broad portfolio of products, including PYLARIFY ® (Piflufolastat F18), a PSMA PET imaging. Our products have practical applications in oncology, cardiology and more. “PYLARIFY has the potential to contribute meaningful and actionable information that can be used to personalize treatment plans in men with low PSA levels,” said Dr. com.